MX388579B - Combinacion de un compuesto de cromeno y un segundo agente activo. - Google Patents
Combinacion de un compuesto de cromeno y un segundo agente activo.Info
- Publication number
- MX388579B MX388579B MX2018008433A MX2018008433A MX388579B MX 388579 B MX388579 B MX 388579B MX 2018008433 A MX2018008433 A MX 2018008433A MX 2018008433 A MX2018008433 A MX 2018008433A MX 388579 B MX388579 B MX 388579B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- combination
- chromene compound
- active agent
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276713P | 2016-01-08 | 2016-01-08 | |
| US201662277225P | 2016-01-11 | 2016-01-11 | |
| PCT/US2017/012737 WO2017120591A1 (en) | 2016-01-08 | 2017-01-09 | Combination of a chromene compound and a second active agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008433A MX2018008433A (es) | 2019-03-28 |
| MX388579B true MX388579B (es) | 2025-03-20 |
Family
ID=59274050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008433A MX388579B (es) | 2016-01-08 | 2017-01-09 | Combinacion de un compuesto de cromeno y un segundo agente activo. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20170196835A1 (OSRAM) |
| EP (1) | EP3400218A4 (OSRAM) |
| JP (1) | JP6942726B2 (OSRAM) |
| KR (1) | KR20180100652A (OSRAM) |
| CN (1) | CN108779091B (OSRAM) |
| AU (1) | AU2017206108B2 (OSRAM) |
| CA (1) | CA3010848A1 (OSRAM) |
| MX (1) | MX388579B (OSRAM) |
| WO (1) | WO2017120591A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220130249A (ko) | 2016-05-26 | 2022-09-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | Egfr 억제제 화합물 |
| CN110869055B (zh) * | 2017-07-20 | 2023-04-28 | 国立大学法人北海道大学 | 靶向pd-1/pd-l1的抑制剂与cox-2抑制剂的组合使用 |
| TR201900059A2 (tr) | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| TWI869398B (zh) * | 2019-05-10 | 2025-01-11 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| EP4051260A4 (en) * | 2019-10-28 | 2023-12-06 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
| CN115135385B (zh) | 2019-11-12 | 2024-05-10 | 纳米医疗有限公司 | 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法 |
| CA3174675A1 (en) | 2020-04-29 | 2021-11-04 | Relay Therapeutics, Inc. | Pi3k.alpha. inhibitors and methods of use thereof |
| EP4412606A4 (en) * | 2021-10-07 | 2025-09-24 | Relay Therapeutics Inc | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF |
| KR102889598B1 (ko) * | 2023-02-16 | 2025-11-21 | 주식회사 재인알앤피 | 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US20040127470A1 (en) | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| EP2175722A4 (en) | 2007-07-12 | 2010-08-25 | Tragara Pharmaceuticals Inc | PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS |
| CN102757417B (zh) | 2012-06-18 | 2014-09-24 | 中国科学院广州生物医药与健康研究院 | 氘代苯并吡喃类化合物及其应用 |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN103012350B (zh) * | 2012-12-07 | 2015-02-04 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
| CN103044477B (zh) | 2012-12-07 | 2015-08-05 | 中国科学院广州生物医药与健康研究院 | 三甲基硅取代苯并吡喃类化合物及其应用 |
| US9452228B2 (en) * | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
| CN105073128A (zh) * | 2013-04-03 | 2015-11-18 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US11034757B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
-
2017
- 2017-01-09 US US15/401,777 patent/US20170196835A1/en not_active Abandoned
- 2017-01-09 JP JP2018554651A patent/JP6942726B2/ja active Active
- 2017-01-09 CA CA3010848A patent/CA3010848A1/en active Pending
- 2017-01-09 AU AU2017206108A patent/AU2017206108B2/en active Active
- 2017-01-09 EP EP17736519.4A patent/EP3400218A4/en not_active Withdrawn
- 2017-01-09 MX MX2018008433A patent/MX388579B/es unknown
- 2017-01-09 WO PCT/US2017/012737 patent/WO2017120591A1/en not_active Ceased
- 2017-01-09 CN CN201780012465.0A patent/CN108779091B/zh active Active
- 2017-01-09 KR KR1020187022783A patent/KR20180100652A/ko not_active Ceased
-
2022
- 2022-05-13 US US17/744,185 patent/US20220265602A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3400218A4 (en) | 2019-09-18 |
| JP2019501224A (ja) | 2019-01-17 |
| EP3400218A1 (en) | 2018-11-14 |
| JP6942726B2 (ja) | 2021-09-29 |
| CN108779091A (zh) | 2018-11-09 |
| CN108779091B (zh) | 2022-12-27 |
| CA3010848A1 (en) | 2017-07-13 |
| AU2017206108B2 (en) | 2021-10-28 |
| KR20180100652A (ko) | 2018-09-11 |
| US20220265602A1 (en) | 2022-08-25 |
| AU2017206108A1 (en) | 2018-08-02 |
| MX2018008433A (es) | 2019-03-28 |
| WO2017120591A1 (en) | 2017-07-13 |
| US20170196835A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388579B (es) | Combinacion de un compuesto de cromeno y un segundo agente activo. | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| CY1124328T1 (el) | Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| SG10201810615VA (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
| PH12017502407B1 (en) | Fused pyrimidine compound or salt thereof | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EP4349997A3 (en) | Anti-garp antibody | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA201991412A1 (ru) | Ингибиторы поли(адф-рибоза)полимеразы (parp) | |
| HK1258570A1 (zh) | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| EA201991772A1 (ru) | Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| NZ629469A (en) | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| BR112018072887A2 (pt) | método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto | |
| PH12016501733A1 (en) | Pharmaceutical composition for preventing or treating skin rash |